RXST
RxSight, Inc.
Ophthalmic Goods- 売上
- $134m
- 時価総額
- $250m
株価 $6.05 · 100株 605円
白内障手術後の患者向けに光で度数を調整できる眼内レンズと関連機器を提供し収益を得る
| 期 | 23/12 | 24/12 | 25/12 |
|---|---|---|---|
| 売上 | $89m | $140m | $134m |
| 成長率 | — | 57.1% | ▲3.9% |
| 総利益 | $54m | $99m | $103m |
| 総利益率 | 60.4% | 70.7% | 76.6% |
| 販管費 | $75m | $101m | $113m |
| 販管費率 | 84.0% | 72.5% | 83.8% |
| 営利 | ▲$50m | ▲$37m | ▲$48m |
| 営利率 | ▲56.2% | ▲26.3% | ▲35.8% |
| 純利益 | ▲$49m | ▲$27m | ▲$39m |
| PBR | 1.6 | 0.9 | 0.9 |
| PSR | 2.8 | 1.8 | 1.9 |
| PGPR | 4.6 | 2.5 | 2.4 |
| PER | — | — | — |
| ﾈｯﾄｷｬｯｼｭ | $10m | $17m | $20m |
| EV/EBITDA | — | — | — |
| Rule of 40 | — | 31% | ▲40% |
| セールス効率 | — | 170% | 36% |
※Rule of 40は売上成長率＋営業利益率、セールス効率は売上総利益増加÷販管費増加（販管費増のときのみ）